Evaluation of Fiasp® (Fast Acting Insulin Aspart) in 670G Hybrid Closed-Loop Therapy

Inclusion Criteria

• •1. Clinical diagnosis of type 1 diabetes and using 670G pump for at least 1 month, and willing to have the 670G pump downloaded into a Carelink Clinical research database.
• •2. The diagnosis of type 1 diabetes is based on the investigator's judgment; C-peptide level and antibody determinations are not needed.
• •3. Age ≥18 years
• •4. Using Novolog or Fiasp® insulin at time of enrollment
• •5. Willing to use Fiasp® insulin
• •6. Total daily insulin dose is at least 0.3 units/kg/day
• •7. Usual carbohydrate intake is at least 60 grams a day, and willing to have at least 25 grams of carbohydrates for breakfast
• •8. For females, not currently known to be pregnant
• •9. An understanding of and willingness to follow the protocol and sign the informed consent
• •10. Willing to have photographs taken of their infusion sites
• •11. Willing to download their 670G pump every 1-2 weeks to a research Carelink account
• •12. Willingness to answer a brief online questionnaire every 2 weeks
• •13. Must be able to understand spoken or written English
• •14. For subjects participating in Part 2 of this study they will need to be using Fiasp® as part of their usual care
• •15. Hemoglobin A1c between 6 and 10% at the time of enrollment